The outcomes included MACE as well as major kidney disease
doi: 10.1172/JCI146353 Summary Keywords GIP, GLP-1, tirzepatide, basal insulin, type 2 diabetes, obesity, body weight, hypoglycemia Citation Lisco G, De Tullio A, Disoteo O, De Geronimo V, Piazzolla G, De Pergola G, Giagulli VA, Jirillo E, Guastamacchia E, Sabb C and Triggiani V (2022) Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
Food and Drug Administration (FDA) has even approved some formulations of semaglutide as weight loss treatments
Bioavailability: Highly bioavailable via parenteral routes
Our DSIP 5 mg lots are produced in China in GMP-style peptide facilities and supplied as high-purity (99%) powder in amber vials for light-sensitive applications